Search alternatives:
significant cause » significant change (Expand Search), significant changes (Expand Search), significant gap (Expand Search)
significant hits » significant units (Expand Search), significant bias (Expand Search), significant anti (Expand Search)
cause decrease » caused decreased (Expand Search), use decreased (Expand Search), causes increased (Expand Search)
hits decreased » visits decreased (Expand Search), costs decreased (Expand Search), rate decreased (Expand Search)
Showing 1 - 20 results of 13,756 for search '(( significant cause decrease ) OR ( significant hits decreased ))', query time: 0.56s Refine Results
  1. 1
    Validation of primary screen hits reveals compounds that recapitulate increased spheroid size (swell) or decreased MUC5AC in the lumen.

    Validation of primary screen hits reveals compounds that recapitulate increased spheroid size (swell) or decreased MUC5AC in the lumen. by Pranjali Beri (14945400)

    Published 2023
    “…Compounds that appeared to cause toxicity were identified by observing a significant decrease in spheroid counts in the swell readout or a significant decrease in the total nuclear intensity of the MUC5AC ratio readout. …”
    Save to List
    Saved in:
  2. 2
    Treatment with ICs causes a significant decrease in podocyte proliferation.

    Treatment with ICs causes a significant decrease in podocyte proliferation. by George Haddad (470789)

    Published 2023
    Save to List
    Saved in:
  3. 3
    Bootstrapped LIWC negative word ratio (LWNR) around the hit date for each hurricane and location.

    Bootstrapped LIWC negative word ratio (LWNR) around the hit date for each hurricane and location. by Krishna Bathina (12883820)

    Published 2022
    Save to List
    Saved in:
  4. 4
    Spheroid size changes due to primary mucus reduction hits and mucus changes due to primary swell hits.

    Spheroid size changes due to primary mucus reduction hits and mucus changes due to primary swell hits. by Pranjali Beri (14945400)

    Published 2023
    Save to List
    Saved in:
  5. 5
    Species richness decreases significantly with increasing percent disturbance.

    Species richness decreases significantly with increasing percent disturbance. by Catherine L. Cardelús (6429320)

    Published 2019
    Save to List
    Saved in:
  6. 6
    Diagram of the mechanism by which PFAS causes a decrease in constipation.

    Diagram of the mechanism by which PFAS causes a decrease in constipation. by Yifan Zhao (659636)

    Published 2024
    Save to List
    Saved in:
  7. 7
    PRV-induced infertility is caused by decreased P4 level.

    PRV-induced infertility is caused by decreased P4 level. by Bing-Qian Su (8616981)

    Published 2024
    Save to List
    Saved in:
  8. 8
    Encapsulation efficiency significantly decreases with increasing starting bacterial concentration.

    Encapsulation efficiency significantly decreases with increasing starting bacterial concentration. by Kelly C. Freudenberger Catanzaro (6701789)

    Published 2022
    Save to List
    Saved in:
  9. 9
    M<sup>pro</sup> confers a significant reduction in growth in yeast caused by decreases in a variety of cellular proteins.

    M<sup>pro</sup> confers a significant reduction in growth in yeast caused by decreases in a variety of cellular proteins. by Jin Ou (16914305)

    Published 2023
    Save to List
    Saved in:
  10. 10
    Mononucleation of the intestine causes an X chromosome specific decrease in expression levels.

    Mononucleation of the intestine causes an X chromosome specific decrease in expression levels. by Lotte M. van Rijnberk (3716362)

    Published 2022
    Save to List
    Saved in:
  11. 11
    Knockout of <i>CLTC</i> caused a decrease infection of SFTSV.

    Knockout of <i>CLTC</i> caused a decrease infection of SFTSV. by Tiezhu Liu (4175812)

    Published 2023
    Save to List
    Saved in:
  12. 12
    MPA does not cause significant apoptosis effect in CN and CO.

    MPA does not cause significant apoptosis effect in CN and CO. by Intan Sofia Omar (10451088)

    Published 2022
    Save to List
    Saved in:
  13. 13
    Networks favouring more connected individuals results in a significant decrease to the likelihood of network recovery.

    Networks favouring more connected individuals results in a significant decrease to the likelihood of network recovery. by Adam Lee Miles (14123916)

    Published 2024
    Save to List
    Saved in:
  14. 14
    Geniposide (Gen) significantly decreased the content of Hyp in bleomycin-induced PF mice’s lung tissue.

    Geniposide (Gen) significantly decreased the content of Hyp in bleomycin-induced PF mice’s lung tissue. by Jian-Bin Yin (19556105)

    Published 2024
    Save to List
    Saved in:
  15. 15
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  16. 16
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  17. 17
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  18. 18
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  19. 19
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  20. 20
    Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width.

    Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width. by Maral Budak (6680351)

    Published 2021
    Save to List
    Saved in:

Search Tools: